Peregrine Pharmaceuticals has reported top-line results from a Phase II study evaluating bavituximab in combination with gemcitabine in stage IV pancreatic cancer patients.

The 70 patient open-label, randomised study demonstrated that the combination of bavituximab and gemcitabine showed more than a doubling of overall response rates (ORR) and an improvement in overall survival (OS) when compared with gemcitabine alone (control arm).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Peregrine medical oncology head Dr Kerstin Menander said; "Although the median overall survival improvement is modest, further analysis of the data including subgroups shows some very interesting and potentially promising trends."

"The combination of bavituximab and gemcitabine showed more than a doubling of overall response rates (ORR) and an improvement in overall survival (OS) when compared with gemcitabine alone."

According to the data, patients treated with a combination of bavituximab and gemcitabine had a 28% tumour response rate as compared to 13% in the control arm.

The primary endpoint of the trial is the median OS, which was 5.6 months for the bavituximab plus gemcitabine arm and 5.2 months for the control arm (hazard ratio = 0.75).

See Also:

Bavituximab in combination with gemcitabine was safe and well-tolerated with the occurrence of similar adverse events in both arms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Peregrine clinical and regulatory affairs vice president Joseph Shan said the company is evaluating the next steps to advance the bavituximab pancreatic programme.

"Subgroup analyses from the trial are yielding additional information that we believe will be important in guiding the anticipated future development of bavituximab in this challenging indication," Shan said.

"We are considering potential development pathways that would allow us to take advantage of bavituximab’s broad potential when combined with other cancer agents."